Sitryx Therapeutics has initiated a Phase 1a clinical trial of SYX-5219, a first-in-class oral PKM2 modulator designed to provide disease-modifying treatment for atopic dermatitis.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.